UNIGE document Scientific Article
previous document  unige:151338  next document
add to browser collection
Title

Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy

Authors
Painter, Chris
Hearmon, Natalie
Eddowes, Lucy
Published in JHEP Reports : Innovation in hepathology. 2021, vol. 3, no. 3, 100279
Abstract Patients hospitalised because of mental illness often have risk factors for contracting HCV. Scaling-up HCV screening for all psychiatric inpatients as a case-detection strategy for viral elimination is underexplored. This study aimed to evaluate the cost-effectiveness of scaling-up HCV screening and treatment for psychiatry hospital admissions in Switzerland vs. the current standard-of-care risk-based approach, where only those with a history of substance misuse disorder are offered testing.
Keywords Cost-effectiveness modelDAA, direct-acting antiviralDirect-acting antiviral agentsHepatitis C infectionICER, Incremental cost-effectiveness ratioNMB, net monetary benefitPMI, patients with mental illnessesPSA, probabilistic sensitivity analysisPsychiatric disorderQALY, quality-adjusted life-yearScreening strategyWTP, willingness-to-pay
Identifiers
PMID: 34522875
Full text
Structures
Research groups Etudes et traitement de l'hépatite C et B (554)
Psychopathologie clinique et expérimentale (987)
Citation
(ISO format)
GIRARDIN, François et al. Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. In: JHEP Reports : Innovation in Hepatology, 2021, vol. 3, n° 3, p. 100279. doi: 10.1016/j.jhepr.2021.100279 https://archive-ouverte.unige.ch/unige:151338

138 hits

57 downloads

Update

Deposited on : 2021-04-29

Export document
Format :
Citation style :